Steven Coutre
Credentials: · ·
History
- 1986–1989
Internal Medicine
Research
Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia
New England Journal of Medicine · 2013 · 1,914 citations
Idelalisib and rituximab in relapsed chronic lymphocytic leukemia
New England Journal of Medicine · 2014 · Co-first of 27 authors · 1,384 citations
Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia
New England Journal of Medicine · 2014 · 1,369 citations
- JB
39 papers
- SO
35 papers
29 papers
27 papers
25 papers
- DJ
24 papers
24 papers
23 papers
Grants
- 2014–2019
Stanford University NCTN- Network Lead Academic Site
National Cancer Institute · U10
PI · $2.8M · Stanford University
- 2000–2008
General Clinical Research Center
National Center for Research Resources · M01
Project lead · $227.4K · Stanford University
- 1992
Functional Consequences of Natural Hiv-1 Env Gene Divers
National Institute of Allergy and Infectious Diseases · K11
Contact PI · $40.7K · Stanford University
Clinical trials
- 2017–2021
Venetoclax and Ibrutinib in Patients With Relapsed/Refractory CLL or SLL
Principal investigator · Completed · Phase 2
Steven E. Coutre
- 2016–2017
Principal investigator · Terminated · Phase 1
Steven E. Coutre
- 2016–2019
Shotgun Sequencing in Diagnosing Febrile Neutropenia in Patients With Acute Myeloid Leukemia
Principal investigator · Completed
Stanford University
- 2013–2014
Temozolomide Plus Vorinostat in Relapse/Refractory Acute Myeloid Leukemia (AML)
Principal investigator · Completed · Phase 2
Steven E. Coutre